SGLT2 inhibitor

This page covers all SGLT2 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SGLT2 (sodium-glucose cotransporter 2), SGLT2, SGLT2 (Sodium-Glucose Cotransporter 2).

Targets

SGLT2 (sodium-glucose cotransporter 2) · SGLT2 · SGLT2 (Sodium-Glucose Cotransporter 2) · SGLT1 and SGLT2 · SGLT2 (Sodium-glucose cotransporter 2)

Marketed (38)

• Invokana Pill · AgelessRx · Diabetes
  Invokana (canagliflozin) inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
• Empagliflozin (Jardiance®) · University Hospital Tuebingen · Diabetes
  Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• B55R1 and B55R2 · AJU Pharm Co., Ltd. · Diabetes
  B55R1 and B55R2 are inhibitors of the sodium-glucose cotransporter 2 (SGLT2).
• CDobi · Services Hospital, Lahore · Diabetes
  CDobi is a medication that works by inhibiting the activity of a specific enzyme.
• senfrol monotherapy · Peking University Third Hospital · Diabetes
  Senfrol monotherapy works by inhibiting the activity of a specific enzyme.
• phase II · Suzhou Genhouse Bio Co., Ltd. · Diabetes
  This drug works by inhibiting the activity of a specific enzyme.
• A1 · Breath of Life International Pharma Ltd · Diabetes
  A1 works by inhibiting the action of a specific enzyme.
• Canagliflozin (TA-7284) · Tanabe Pharma Corporation · Diabetes
  Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.
• Dapagliflozin (Forxiga) · National Institute of Cardiology, Warsaw, Poland · Diabetes, Cardiovascular
  Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• CTM Boost · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Diabetes
  CTM Boost is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• Sodium-glucose cotransporter 2 inhibitor · Queen's University, Belfast · Diabetes, Cardiovascular, Nephrology
  SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion.
• Antihyperglycemic Medication · Merck Sharp & Dohme LLC · Diabetes
  This drug reduces blood glucose by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidney, allowing excess glucose to be excreted in urine.
• NBF · Universidad Complutense de Madrid · Diabetes
  NBF is a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• SGLT2 Inhibition · Zhongshan Hospital Xiamen University · Diabetes
  SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• Weight Based Group · University of Colorado, Denver · Diabetes
  This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
• Oral administration of Ipragliflozin · Asan Medical Center · Diabetes
  Ipragliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.
• SGLT2i · University of Chicago · Diabetes
  SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• FPT-20 · Trieu, Nguyen Thi, M.D. · Diabetes
  FPT-20 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• xin te mie · Xiangbei Welman Pharmaceutical Co., Ltd · Diabetes
  Xin te mie is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• Keverprazan 10 days · Second Affiliated Hospital, School of Medicine, Zhejiang University · Diabetes
  Keverprazan is a selective and reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• GnP · West China Hospital · Diabetes
  GnP is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• Canagliflozin - SGLT2i · Royal Devon and Exeter NHS Foundation Trust · Diabetes
  Canagliflozin blocks the SGLT2 transporter in the kidney to reduce glucose reabsorption, allowing excess glucose to be excreted in urine and lowering blood sugar.
• Control Rx · National and Kapodistrian University of Athens · Diabetes
  Control Rx is used to control blood sugar levels in patients with diabetes.
• SGLT2 Inhibitors · Pharmaceuticals and Medical Devices Agency, Japan · Diabetes, Cardiovascular, Nephrology
  SGLT2 inhibitors block the sodium-glucose cotransporter 2 in the kidney, preventing reabsorption of glucose and increasing urinary glucose excretion.
• Standard treatment strategy · Fundación para la Investigación del Hospital Clínico de Valencia · Diabetes
  This drug works by inhibiting the reabsorption of sodium and water in the kidneys.
• Bexagliflozin tablets · Theracos · Diabetes
  Bexagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
• Comparator monotherapy empagliflozin · The George Institute · Diabetes
  Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
• Ertugliflozin 5 mg · Pfizer · Metabolic
• Ertugliflozin 15 mg · Pfizer · Metabolic
• Maintenance treatment · RWTH Aachen University · Diabetes
  This drug works by inhibiting the reabsorption of sodium in the kidneys, leading to increased excretion of sodium and water.
• Empa · Beni-Suef University · Diabetes
  Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.
• Concomitant therapy 14 days · Incheon St.Mary's Hospital · Diabetes
  This drug is used to treat various conditions by inhibiting the reabsorption of sodium and water in the kidneys.
• SGLT2 inhibitor · University of Minnesota · Diabetes, Cardiovascular, Nephrology
  SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, preventing glucose reabsorption and promoting urinary glucose excretion.
• North Star · Neuvosyn Laboratories, LLC · Diabetes
  North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• LG-group · Medical University of Vienna · Diabetes
  LG-group drugs are used to treat type 2 diabetes by lowering blood sugar levels.
• Empagliflozin (EMPA) · University of Sao Paulo · Diabetes
  Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• Dapagliflozin (DAPA) · Ottawa Heart Institute Research Corporation · Diabetes, Cardiovascular
  Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
• A5 · Breath of Life International Pharma Ltd · Diabetes
  A5 is a medication that works by inhibiting the action of a specific enzyme.

Phase 3 pipeline (162)

• TGRX-678 · Shenzhen TargetRx Co., Ltd. · Diabetes
  TGRX-678 is a small molecule that targets the SGLT2 receptor.
• TJO-087 · Taejoon Pharmaceutical Co., Ltd. · Diabetes
  TJO-087 is a small molecule that targets the SGLT2 receptor.
• TAK-755 · Takeda · Diabetes
  TAK-755 is a small molecule that targets the SGLT2 receptor.
• Placebo to ZSP1273 · Guangdong Raynovent Biotech Co., Ltd · Diabetes
  ZSP1273 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• GC3102C · Green Cross Corporation · Diabetes
  GC3102C is a small molecule that targets the SGLT2 receptor.
• APSCTC · Apsen Farmaceutica S.A. · Diabetes
  APSCTC is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• Zilbrix™ · GlaxoSmithKline · Diabetes
  Zilbrix inhibits the activity of a specific enzyme.
• N0877 · Eurofarma Laboratorios S.A. · Diabetes
  N0877 is a small molecule drug that targets the SGLT2 receptor.
• GODEX · Yoon Jun Kim · Diabetes
  GODEX is a small molecule that targets the SGLT2 receptor.
• BL-B01D1 · Sichuan Baili Pharmaceutical Co., Ltd. · Diabetes
  BL-B01D1 is a small molecule drug that targets the SGLT2 receptor.
• BL 3000 · Biolab Sanus Farmaceutica · Diabetes
  BL 3000 is a small molecule that targets the SGLT2 receptor.
• AC-170 0% · Aciex Therapeutics, Inc. · Diabetes
  AC-170 is a small molecule that targets the SGLT2 receptor.
• Placebo/dapagliflozin · AstraZeneca · Diabetes, Cardiovascular
  Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
• KI1107 4 Capsules, QD · Kuhnil Pharmaceutical Co., Ltd. · Diabetes
  KI1107 is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• Placebo matching ertugliflozin · Merck Sharp & Dohme LLC · Diabetes
  Ertugliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting glucose excretion in the urine.
• TPN171H · Vigonvita Life Sciences · Diabetes
  TPN171H is a small molecule that targets the SGLT2 receptor.
• UB-851 · UBI Pharma Inc. · Diabetes
  UB-851 is a small molecule that targets the SGLT2 receptor.
• QL0911 · Qilu Pharmaceutical Co., Ltd. · Diabetes
  QL0911 is a small molecule drug that targets the SGLT2 receptor.
• QL1209 · Qilu Pharmaceutical Co., Ltd. · Diabetes
  QL1209 is a small molecule that targets the SGLT2 receptor.
• QL1206 · Qilu Pharmaceutical Co., Ltd. · Diabetes
  QL1206 is a small molecule drug that targets the SGLT2 receptor.
• RAPAE01 · HK inno.N Corporation · Diabetes
  RAPAE01 is a small molecule that targets the SGLT2 receptor.
• VER-01 · Vertanical GmbH · Diabetes
  VER-01 is a small molecule that targets the SGLT2 receptor.
• DW16012 · Daewon Pharmaceutical Co., Ltd. · Diabetes
  DW16012 is a small molecule that targets the SGLT2 receptor.
• DW51212 · Daewon Pharmaceutical Co., Ltd. · Diabetes
  DW51212 is a small molecule drug that targets the SGLT2 receptor.
• ELGN-2112 · Elgan Pharma Ltd. · Diabetes
  ELGN-2112 is a small molecule that targets the SGLT2 receptor.
• Placebo matching with Dapagliflozin · AstraZeneca · Diabetes, Cardiovascular
  Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
• VC005 · Jiangsu vcare pharmaceutical technology co., LTD · Diabetes
  VC005 is a small molecule that targets the SGLT2 receptor.
• VC005 high dose group · Jiangsu vcare pharmaceutical technology co., LTD · Diabetes
  VC005 is a small molecule that targets the SGLT2 receptor.
• RLD2001-1 · Hanmi Pharmaceutical Company Limited · Diabetes
  RLD2001-1 is a small molecule that targets the SGLT2 receptor.
• RPH-104 · R-Pharm Overseas, Inc. · Diabetes
  RPH-104 is a small molecule that targets the SGLT2 receptor.
• AHB-137 · AusperBio Therapeutics Inc. · Diabetes
  AHB-137 is a small molecule that targets the SGLT2 receptor.
• JW0201 · JW Pharmaceutical · Diabetes
  JW0201 is a small molecule that targets the SGLT2 receptor.
• SDN-037 · Sun Pharma Advanced Research Company Limited · Diabetes
  SDN-037 is a small molecule that targets the SGLT2 receptor.
• SG001 · Shanghai JMT-Bio Inc. · Diabetes
  SG001 is a small molecule drug that targets the SGLT2 receptor.
• PK101 · PMG Pharm Co., Ltd · Diabetes
  PK101 is a small molecule that targets the SGLT2 receptor.
• MDR-001 · MindRank AI Ltd · Diabetes
  MDR-001 is a small molecule that targets the SGLT2 receptor.
• Sotagliflozin High Dose · University of California, San Diego · Diabetes
  Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, which helps to reduce glucose reabsorption in the kidneys and intestines.
• SY-3505 Capsules · Shouyao Holdings (Beijing) Co. LTD · Diabetes
  SY-3505 Capsules is a small molecule that targets the SGLT2 receptor.
• V212 · Merck Sharp & Dohme LLC · Diabetes
  V212 is a small molecule that targets the SGLT2 receptor.
• STI-1558 · Zhejiang ACEA Pharmaceutical Co. Ltd. · Diabetes
  STI-1558 is a small molecule drug that targets the SGLT2 receptor.